A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

NCT06424626 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Mucosal Melanoma
Metastatic Melanoma

Interventions

DRUG: AK104+Axitinib
DRUG: AK112+Axitinib

Sponsor

Peking University Cancer Hospital & Institute